Sec. Cancer Molecular Targets and Therapeutics
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1081632
Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition
- 1Department of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), Novara, Italy
- 2School of Life and Health Sciences, Aston University, Birmingham, United Kingdom
- 3Laboratory of Cellular Biochemistry and Molecular Biology, Centro di Ricerca in Biochimica E Nutrizione dello Sport (CRIBENS), Catholic University of the Sacred Heart, Milan, Italy
- 4Department of Health Science, University of Piemonte Orientale (UPO), Novara, Italy
- 5Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
A corrigendum on
CDKN2A determines mesothelioma cell fate to EZH2 inhibition
by Pinton G, Wang Z, Balzano C, Missaglia S, Tavian D, Boldorini R, Fennell DA, Griffin M and Moro L (2021). Front. Oncol. 11:678447. doi: 10.3389/fonc.2021.678447
In the original article, there was an error in the Funding statement as published. The correct funding statement is “The authors acknowledge the financial support of project HERMES (HEreditary Risk in MESothelioma) and Università del Piemonte Orientale (Bando ricerca locale 2019)”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: malignant pleural mesothelioma, EZH2 inhibitor, CDKN2A/p16ink4a, TG2, multicellular spheroids
Citation: Pinton G, Wang Z, Balzano C, Missaglia S, Tavian D, Boldorini R, Fennell DA, Griffin M and Moro L (2022) Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition. Front. Oncol. 12:1081632. doi: 10.3389/fonc.2022.1081632
Received: 27 October 2022; Accepted: 31 October 2022;
Published: 23 November 2022.
Approved by:Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2022 Pinton, Wang, Balzano, Missaglia, Tavian, Boldorini, Fennell, Griffin and Moro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Laura Moro, email@example.com; Giulia Pinton, firstname.lastname@example.org